PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 146 filers reported holding PROGENICS PHARMACEUTICALS IN in Q3 2017. The put-call ratio across all filers is 1.47 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $22,936,000 | +0.7% | 4,506,284 | +0.0% | 0.11% | -6.0% |
| Q3 2019 | $22,768,000 | -18.0% | 4,504,094 | +0.1% | 0.12% | -17.6% |
| Q2 2019 | $27,763,000 | +32.7% | 4,499,708 | -0.2% | 0.14% | +27.9% |
| Q1 2019 | $20,919,000 | +10.8% | 4,508,430 | +0.3% | 0.11% | -6.7% |
| Q4 2018 | $18,880,000 | -32.3% | 4,495,365 | +1.1% | 0.12% | -11.9% |
| Q3 2018 | $27,868,000 | -22.3% | 4,444,673 | -0.4% | 0.14% | -30.1% |
| Q2 2018 | $35,870,000 | +7.5% | 4,461,482 | -0.2% | 0.19% | +6.6% |
| Q1 2018 | $33,352,000 | +35.4% | 4,470,838 | +7.5% | 0.18% | +34.1% |
| Q4 2017 | $24,629,000 | -23.5% | 4,160,760 | -0.1% | 0.14% | -27.0% |
| Q3 2017 | $32,210,000 | +18.2% | 4,166,919 | +3.9% | 0.18% | +12.8% |
| Q2 2017 | $27,243,000 | +8.5% | 4,012,366 | +50.8% | 0.16% | +3.8% |
| Q1 2017 | $25,111,000 | +9.1% | 2,660,121 | -0.2% | 0.16% | +4.6% |
| Q4 2016 | $23,027,000 | – | 2,665,264 | – | 0.15% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Phocas Financial Corp. | 1,033,328 | $6,376,000 | 0.68% |
| ARDSLEY ADVISORY PARTNERS LP | 650,000 | $4,011,000 | 0.63% |
| Worth Venture Partners, LLC | 138,357 | $853,000 | 0.47% |
| RICE HALL JAMES & ASSOCIATES, LLC | 2,242,503 | $13,836,000 | 0.46% |
| HIGHLAND CAPITAL MANAGEMENT LP | 716,880 | $4,423,000 | 0.26% |
| FARALLON CAPITAL MANAGEMENT LLC | 5,543,386 | $34,203,000 | 0.22% |
| Point72 Asset Management, L.P. | 5,858,749 | $36,148,000 | 0.19% |
| PINNACLE ASSOCIATES LTD | 1,298,723 | $8,013,000 | 0.19% |
| Fosun International Ltd | 472,580 | $2,750,000 | 0.18% |
| J. Goldman & Co LP | 400,000 | $2,468,000 | 0.17% |